Tumor antigens for determining cancer therapy
The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
1. A method for treating triple negative breast cancer in a patient comprising
a) detecting the expression pattern of a set of tumor antigens in a sample from the patient, wherein the set of tumor antigens comprises CXorf61, CAGE1, and PRAME;
b) diagnosing the patient as needing a cancer therapy regimen when CXorf61, CAGE1, and PRAME are expressed; and
c) treating the patient with an immunotherapeutic that targets the set of tumor antigens expressed in the patient.
2. The method of claim 1 wherein the sample comprises cancer cells.
3. The method of claim 1 wherein detecting the expression pattern comprises a quantitative and/or qualitative determination of the expression of the tumor antigens.
4. The method of claim 1 wherein detecting the expression pattern comprises determining the expression of RNA and/or protein of the tumor antigens.
5. A method for treating triple negative breast cancer in a patient comprising administering to said patient an immunotherapeutic targeting each tumor antigen of a set of tumor antigens, wherein the set of tumor antigens comprises CXorf6, CAGE1, and PRAME.
6. The method of claim 5 which comprises inducing a cellular immune response in the patient against each tumor antigen of the set of tumor antigens.
7. The method of claim 6 wherein the cellular immune response is induced by administering a vaccine providing one or more T cell epitopes of each tumor antigen of the set of tumor antigens to the patient.